Human Antibodies in Cancer and Autoimmune Disease

Ditzel, Henrik J.

doi:10.1385/ir:21:2-3:185

Cited by 16 publications

(5 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serological identification of antigens by recombinant expression cloning (termed SEREX), which involves bacterial expression of cDNA libraries derived from tumor tissues and screening the recombinant proteins with autologous serum, has pioneered the combinatorial search for tumor antigens [115]. The list of disease antigens for which humoral immune response has been detected continues to grow, and is reviewed elsewhere [116,117]. Several antibodies have been approved by the US Food and Drug Administration (FDA) and have been used as therapeutics in the clinic for several years [101,118].…”

Section: Antibody Librariesmentioning

confidence: 99%

Display technologies: Application for the discovery of drug and gene delivery agents☆

Сергеева

Kolonin

Molldrem

et al. 2006

Advanced Drug Delivery Reviews

222

170

View full text Add to dashboard Cite

Recognition of molecular diversity of cell surface proteomes in disease is essential for the development of targeted therapies. Progress in targeted therapeutics requires establishing effective approaches for high-throughput identification of agents specific for clinically relevant cell surface markers. Over the past decade, a number of platform strategies have been developed to screen polypeptide libraries for ligands targeting receptors selectively expressed in the context of various cell surface proteomes. Streamlined procedures for identification of ligand-receptor pairs that could serve as targets in disease diagnosis, profiling, imaging and therapy have relied on the display technologies, in which polypeptides with desired binding profiles can be serially selected, in a process called biopanning, based on their physical linkage with the encoding nucleic acid. These technologies include virus/phage display, cell display, ribosomal display, mRNA display and covalent DNA display (CDT), with phage display being by far the most utilized. The scope of this review is the recent advancements in the display technologies with a particular emphasis on molecular mapping of cell surface proteomes with peptide phage display. Prospective applications of targeted compounds derived from display libraries in the discovery of targeted drugs and gene therapy vectors are discussed.

show abstract

Section: Antibody Librariesmentioning

confidence: 99%

Display technologies: Application for the discovery of drug and gene delivery agents☆

Сергеева

Kolonin

Molldrem

et al. 2006

Advanced Drug Delivery Reviews

222

170

View full text Add to dashboard Cite

show abstract

“…By expressing RBC antibodies on phage particles and using phage antibodies as the antiglobulin reagent, it is estimated that the production of an amount of an antibody sufficient for about 1 million typing reactions would require as little as 2 L of the bacterial culture to be grown overnight 7 . The phage display technique and subsequent molecular genetic manipulations also permit the preparation of MoAbs to human cells in nonhuman primates, 13 which would obviate the need for alloimmunized human donors and might produce antibodies that otherwise would not be produced by healthy human subjects because of immune tolerance, such as antibodies to antigens overexpressed on tumor cells 15–17 …”

Section: Production Of Typing Reagentsmentioning

confidence: 99%

The phage display technique and transfusion medicine

Jarolím¹

2001

Transfusion

View full text Add to dashboard Cite

“…In the past a few decades, the autoantisera from patients with certain autoimmune diseases, such as systemic lupus erythematosus and scleroderma polymyositis, have been a valuable and important resource for finding new proteins, including some well known proteins (1)(2)(3)(4). Centromere-associated proteins (5)(6)(7)(8), RNA polymerase I (9), DNA topoisomerase I (10), and 70-kDa autoantigen of U1-small nuclear ribonuclease (11) are only a few examples.…”

mentioning

confidence: 99%

Identification and Characterization of a Novel Cytoplasm Protein ICF45 That Is Involved in Cell Cycle Regulation

Guo

Lei

et al. 2004

Journal of Biological Chemistry

View full text Add to dashboard Cite

A novel cytoplasm protein, interphase cytoplasm foci protein 45 kDa (ICF45), was identified by screening the cDNA expression library for HeLa cells with serum from an autoimmune patient. The complete cDNA sequence of ICF45 was determined to be 1.32 kb and to encode 298 amino acids with an apparent molecular mass of 45 kDa. The ICF45 transcripts were detected in different tissues and were relatively rich in human liver and lung tissues but scarce in brain tissue. Immunofluorescence with anti-ICF45-specific antibodies demonstrated that ICF45 is strongly expressed in interphase and cannot be seen in mitosis. The subcellular localization of ICF45 and fusion proteins GFP-ICF45, ICF45-GFP, and HA-ICF45 showed ICF45 centralized into 1-2 dots in the cytoplasm and always near the nuclear membrane. The staining foci of ICF45 appeared to be slightly larger than centrosomes and in some cases were found to colocalize with centrosomes. After effectively silencing the ICF45 by RNAi, the growth and proliferation of the cells were significantly inhibited, and p53 was detected to be up-regulated. The silencing of ICF45 also resulted in an appearance of polycentrosome and multinuclear cells, which finally went to apoptosis. Our results suggest that ICF45 is a highly conserved novel protein, which is expressed in a cell cycle-dependent manner and seemed to be involved in cell cycle progression and cell proliferation.In the past a few decades, the autoantisera from patients with certain autoimmune diseases, such as systemic lupus erythematosus and scleroderma polymyositis, have been a valuable and important resource for finding new proteins, including some well known proteins (1-4). Centromere-associated proteins (5-8), RNA polymerase I (9), DNA topoisomerase I (10), and 70-kDa autoantigen of U1-small nuclear ribonuclease (11) are only a few examples. The development of some newer techniques, such as RACE, 1 GFP, and RNAi, has been dramatically speeding up the process of identifying new proteins and their function. Moreover, it is to be expected that some nontarget proteins might be caught during screening cDNA library with autoimmune patient sera, and some of these proteins could also be completely new and important. It was during our screening of HeLa cells from the cDNA expression library EXlox with the autoantiserum EJ, which recognizes mammalian centromeres (8, 12), when 11 positive clones were selected in the first round, and one of them was recognized as a centromere nonrelated protein with an apparent molecular mass of 45 kDa. What interested us the most about the protein is that the presence of this novel protein was highly cell cycle-dependent. It exists specifically in interphase cells and cannot be seen in mitosis. More interestingly, this protein was found to centralize into 1 or 2 sharp dots near the nuclear membrane at the cytoplasmic site. It was thus named ICF45 (Interphase Cytoplasmic Foci protein 45 kDa). In this study, we investigated the cellular dynamic distribution of ICF45 by using GFP fusion protein, and we ...

show abstract

Human Antibodies in Cancer and Autoimmune Disease

Cited by 16 publications

References 39 publications

Display technologies: Application for the discovery of drug and gene delivery agents☆

Display technologies: Application for the discovery of drug and gene delivery agents☆

The phage display technique and transfusion medicine

Identification and Characterization of a Novel Cytoplasm Protein ICF45 That Is Involved in Cell Cycle Regulation

Contact Info

Product

Resources

About